Yang Fan, Ni Beibei, Lian Qinghai, Qiu Xiusheng, He Yizhan, Zhang Qi, Zou Xiaoguang, He Fangping, Chen Wenjie
Department of Infectious Diseases, The First People's Hospital of Kashi, The Kashi Affiliated Hospital, Sun Yat-Sen University, Kashi, China.
Biotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Front Genet. 2023 Mar 6;14:1066410. doi: 10.3389/fgene.2023.1066410. eCollection 2023.
Hepatocellular carcinoma (HCC) has become the world's primary cause of cancer death. Obesity, hyperglycemia, and dyslipidemia are all illnesses that are part of the metabolic syndrome. In recent years, this risk factor has become increasingly recognized as a contributing factor to HCC. Around the world, non-alcoholic fatty liver disease (NAFLD) is on the rise, especially in western countries. In the past, the exact pathogenesis of NAFLD that progressed to metabolic risk factors (MFRs)-associated HCC has not been fully understood. Two groups of the GEO dataset (including normal/NAFLD and HCC with MFRs) were used to analyze differential expression. Differentially expressed genes of HCC were verified by overlapping in TCGA. In addition, functional enrichment analysis, modular analysis, Receiver Operating Characteristic (ROC) analysis, LASSO analysis, and Genes with key survival characteristics were analyzed. We identified six hub genes (FABP5, SCD, CCL20, AGPAT9(GPAT3), PLIN1, and IL1RN) that may be closely related to NAFLD and HCC with MFRs. We constructed survival and prognosis gene markers based on FABP5, CCL20, AGPAT9(GPAT3), PLIN1, and IL1RN.This gene signature has shown good diagnostic accuracy in both NAFLD and HCC and in predicting HCC overall survival rates. As a result of the findings of this study, there is some guiding significance for the diagnosis and treatment of liver disease associated with NAFLD progression.
肝细胞癌(HCC)已成为全球癌症死亡的主要原因。肥胖、高血糖和血脂异常都是代谢综合征的组成疾病。近年来,这种风险因素越来越被认为是HCC的一个促成因素。在全球范围内,非酒精性脂肪性肝病(NAFLD)正在上升,尤其是在西方国家。过去,NAFLD进展为与代谢风险因素(MFRs)相关的HCC的确切发病机制尚未完全了解。使用两组GEO数据集(包括正常/NAFLD和伴有MFRs的HCC)来分析差异表达。通过在TCGA中重叠来验证HCC的差异表达基因。此外,还进行了功能富集分析、模块分析、受试者工作特征(ROC)分析、LASSO分析以及具有关键生存特征的基因分析。我们鉴定出六个可能与NAFLD和伴有MFRs的HCC密切相关的枢纽基因(FABP5、SCD、CCL20、AGPAT9(GPAT3)、PLIN1和IL1RN)。我们基于FABP5、CCL20、AGPAT(GPAT3)、PLIN1和IL1RN构建了生存和预后基因标志物。这种基因特征在NAFLD和HCC中以及预测HCC总体生存率方面都显示出良好的诊断准确性。这项研究的结果对与NAFLD进展相关的肝病的诊断和治疗具有一定的指导意义。